Delivered record 2025 results with 44% revenue growth, primarily driven by the 76% year-over-year expansion of lead rare disease asset Cortrophin Gel. Attributed Cortrophin outperformance to successful penetration of specialty indications including nephrology, neurology, and rheumatology, alongside record new patient starts. Leveraged a 'virtuous cycle' where high-performing generics (up 28%) and established brands generate cash flow to fund the capital-intensive transformation into a rare disease lea ...